Olmesartan Medoxomil Amarox (Olmesartan Medoxomil)

Olmesartan medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diastolic heart failure: assists in managing fluid overload and improving cardiac output.
• Post‑myocardial infarction: supports long‑term blood pressure control to lower recurrence risk.

• Olmesartan medoxil binds selectively to angiotensin II type 1 (AT1) receptors on vascular smooth‑muscle cells, blocking the vasoconstrictive and aldosterone‑secreting actions of angiotensin II. This inhibition leads to vasodilation, reduced peripheral resistance, and decreased sodium and water retention, collectively lowering systemic blood pressure.

Adverse reactions to olmesartan medoxomil are generally mild to moderate and vary among patients.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea

Serious or Rare Side Effects

• Angio‑ema
• Hyperkalemia
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevation

Olmesartan medoxomil should be used with caution in several clinical situations.

• Renal impairment: dose may need adjustment and renal function monitored.
• Hepatic impairment: use with caution and monitor liver enzymes.
• Electrolyte disturbances: watch for hyperkalaemia, especially with potassium‑sparing diuretics.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Concomitant use with aliskiren: avoid in patients with diabetes or renal impairment.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan medoxomil can interact with several other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren (in diabetic or renal‑impaired patients): may increase risk of renal dysfunction.
• Potassium‑sparing diuretics (e.g., spironolactone): can cause dangerous hyperkalaemia.
• NSAIDs (high‑dose ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: combined use raises risk of hypotension, hyperkalaemia, and renal impairment.
• Lithium: may increase serum lithium levels, risking toxicity.
• Diuretics (thiazides): may enhance antihypertensive effect and affect electrolyte balance.